BPC-157 (Body Protection Compound-157) is one of the most widely discussed compounds in preclinical peptide research. A synthetic pentadecapeptide of 15 amino acids, it is derived from a partial sequence of a protective protein identified in human gastric juice. Over three decades of published literature — much of it from research groups in Croatia led by Predrag Sikirić — has examined BPC-157 in laboratory models of tissue repair, angiogenesis, gastrointestinal integrity, and musculoskeletal healing.
This article summarizes what the published research actually investigates, the mechanisms researchers focus on, and the practical laboratory considerations for working with the compound. As with everything in our Research Library, this is educational material about a research-use-only compound: nothing here describes or supports human use.
What BPC-157 Is
BPC-157 is a stable gastric pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (molecular weight ≈ 1,419 Da). Two properties distinguish it in the research literature:
Stability. Unlike most peptides, BPC-157 has demonstrated unusual resistance to degradation in gastric juice in laboratory testing — a property that made it a subject of sustained interest in gastrointestinal research models, where most peptides degrade too quickly to study.
Breadth of investigated models. The published literature spans an unusually wide range of experimental systems: gastric and intestinal lesion models, tendon and ligament injury models, muscle crush models, vascular injury models, and nerve regeneration models, among others.
Mechanisms Under Investigation
Preclinical studies have proposed several interlocking mechanisms. Three dominate the literature:
1. Angiogenesis and the VEGF pathway
Multiple studies have examined BPC-157’s influence on the formation of new blood vessels in injury models. Research by Hsieh and colleagues reported that BPC-157 promoted endothelial cell migration and vessel-forming behavior in vitro, with findings implicating the VEGFR2 signaling pathway and its downstream cascade. Because injured tissue depends on restored blood supply, angiogenesis is a central theme in essentially all BPC-157 repair models.
2. The nitric oxide (NO) system
Sikirić’s group has repeatedly reported interactions between BPC-157 and the NO system in preclinical work — including experiments in which the compound’s observed effects were modified by NO synthase blockade (L-NAME) and NO precursors (L-arginine). The NO system regulates vascular tone, platelet behavior, and mucosal defense, which is why researchers treat this interaction as a candidate explanation for effects observed across otherwise unrelated organ models.
3. Growth factor expression and cell migration
In tendon research, Chang and colleagues reported that BPC-157 exposure was associated with increased outgrowth of tendon explants, greater fibroblast survival under oxidative stress, and accelerated cell migration in vitro, with signaling work pointing toward the FAK–paxillin pathway. Upregulation of early growth response protein 1 (EGR-1) and its co-repressor NAB2 has also been reported, which is notable because EGR-1 drives expression of cytokines and growth factors involved in wound repair.
Major Research Areas
Gastrointestinal models. The compound’s origin story is gastric, and GI research remains the deepest part of the literature: experimental lesion models, fistula models, and inflammatory bowel models. Reviews by Sikirić and colleagues catalog this body of work in detail.
Tendon, ligament, and muscle models. A 2019 review by Gwyer, Wragg, and Wilson in Cell and Tissue Research surveyed the preclinical evidence for BPC-157 in musculoskeletal soft-tissue healing, noting consistent positive findings across rodent tendon-transection, ligament-injury, and muscle-crush models — while also emphasizing a limitation researchers should take seriously: the near-total absence of published human data and the concentration of the literature within a small number of research groups.
Vascular and nerve models. Smaller bodies of work examine vessel-injury models (including studies of alternative bypassing pathways after occlusion) and peripheral nerve regeneration models.
Reading the Literature Critically
Honest research sourcing means acknowledging the limitations alongside the findings:
- Preclinical only. The published evidence base is overwhelmingly rodent and in vitro work. Well-controlled published human trial data is essentially absent.
- Concentrated authorship. A large share of the primary literature originates from a small cluster of collaborating labs. Independent replication is comparatively thin — a standard reason for caution when weighing any preclinical literature.
- Model dependence. Effects reported in one injury model do not automatically generalize to others, and mechanisms proposed from signaling studies remain hypotheses under investigation.
None of this makes the compound uninteresting — it makes rigorous sourcing and verified material quality more important, since irreproducible inputs are one of the classic causes of irreproducible results.
Laboratory Considerations
Verification. For research applications, compound identity and purity are the foundation of usable data. Every batch of BPC-157 10mg supplied by Full Scale Peptides is third-party tested for identity and ≥99% purity, with the batch-specific report published in our COA Library before purchase. If you’re new to reading lab reports, our guide on how to read a Certificate of Analysis walks through each section.
Form and stability. BPC-157 is supplied as a lyophilized powder. Lyophilized peptides are stable for extended periods when stored at −20°C, protected from light and humidity.
Reconstitution. In laboratory settings, researchers typically reconstitute lyophilized peptides with bacteriostatic water or sterile solvents appropriate to the experimental protocol. Our storage and handling best practices guide covers temperature, reconstitution, and stability considerations in detail.
Related compounds. BPC-157 is frequently studied alongside TB-500 (thymosin beta-4 fragment) in repair-model research; the combination is available as our Wolverine Blend (BPC-157/TB-500), and with GHK-Cu added as the GLOW Blend.
Summary
BPC-157 sits at the intersection of three well-studied repair mechanisms — angiogenesis via VEGF signaling, the nitric oxide system, and growth-factor-driven cell migration — with a preclinical literature that is broad, largely positive, and honestly limited by its concentration in a few labs and the absence of human data. For laboratories studying tissue repair pathways, it remains one of the most referenced peptides in the field, which is exactly why verified identity and purity matter before any of that literature can be meaningfully built upon.
Browse BPC-157 10mg and its published batch COA, or explore the full catalog of third-party tested research peptides.
Research Use Only. All compounds referenced are intended solely for laboratory research and development purposes. Not for human or veterinary use. This article is educational material and does not describe, encourage, or support any use in humans or animals.
References
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019.
- Seiwerth S, et al. BPC 157 and blood vessels. Current Pharmaceutical Design, 2014.